312 results about "Transmissible disease" patented technology

The present invention relates to various molecular constructs having at least one cellular-targeting element, one protein-targeting element, and one ubiquitin ligase recruitment element, wherein these elements are conjugated in a manner that facilitates cellular uptake and targeted degradation of specific proteins within cells. The present invention further relates to multifunctional proteolysis-targeting chimera conjugates and uses thereof for the treatment of diseases or disorders such as immune and inflammatory diseases, infectious diseases, cardiovascular diseases, endocrine disorders, and various cancers that are otherwise resistant to traditional therapeutic regimens.

The disclosure features anti-tumor necrosis factor receptor superfamily (TNFRSF), anti-tumor necrosis factor superfamily (TNFSF), anti-CD28, and anti-ICOS antibodies and antigen-binding fragments thereof with amino acid modifications at the Fc domain, and the use of these antibodies or antigen-binding fragments to modulate immune response. The antibodies and antigen-binding fragments thereof can be used to treat a wide variety of cancers, autoimmune disorders, neurological disorders, infectious diseases, inflammatory diseases, and transplant rejections.

Embodiments of the invention include compositions and methods related to engineered human mucosal-associated invariant T (eMAIT) cells for off-the-shelf use for clinical therapy for cancer, infectious, and autoimmune diseases. In some embodiments, the eMAIT cells are produced from healthy human donor peripheral blood, cord blood, or G-CSF mobilized peripheral blood. In particular embodiments, the eMAIT cells are produced from a pluripotent stem cell line and therefore can be of unlimited supply. In some embodiments, the eMAIT cells are engineered to express chimeric antigen receptors (CARs), or / and immune regulatory molecules, or / and allorejection resistance molecules. Embodiments of the invention also include compositions of matter comprising polynucleotides encoding mucosal-associated invariant T cell receptor alpha chain polypeptides and / or mucosal-associated invariant T cell receptor beta chain polypeptides.

The invention constructs a universal visual virus molecularly imprinted sensor modified with an anti-protein coating, the sensor uses magnetic Fe3O4 as an imprinting carrier, HBV as a template and dopamine as a functional monomer for imprinting to obtain a molecularly imprinted polymer with a polydopamine coating (PDA), and before the template is removed, the molecular imprinting polymer with the polydopamine coating (PDA) is separated from the template, so that the molecular imprinting polymer with the polydopamine coating (PDA) is obtained. The surface of the PDA layer is covered with a slightly cross-linked PMEO2MA layer through a water precipitation polymerization method, and the polymer can effectively reduce non-specific protein adsorption; and finally, exposing an imprinting cavity of the PDA layer by eluting the template molecules. On the other hand, potassium permanganate (KMnO4) is used as a signal output molecule, and when no target object exists, the strong reducibility of PDA can enable KMnO4 entering the imprinting cavity to be subjected to a color fading reaction. Based on the principle, high-specificity colorimetric visual detection on the HBV is realized. The sensor can be combined with a smart phone through naked eyes to carry out visual semi-quantitative analysis and carry out quantitative detection through ultraviolet rays, and the universality of the sensor can be confirmed through a template replacement experiment. And meanwhile, the sensor shows an excellent cost advantage. The diagnosis which is high in sensitivity, low in cost and capable of achieving rapid visualization shows huge potential in practical application, and particularly has important application value in infectious disease screening and monitoring work in areas with limited resources.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present invention relates to a novel lipid compound for tissue-specific delivery, and a lipid nano-particle (LNP) composition comprising the same, the lipid nano-particle comprising a modified lipid compound as a component, according to the present invention, internal active substances are selectively delivered into cells of specific tissues such as lymph nodes, spleen, retina, cancer, brain, liver and the like in vivo, thereby preventing side effects and safely exhibiting a desired level of effect. The tissue-specific non-viral LNP delivery vectors can be effectively used for prevention of infectious diseases and treatment of rare and refractory (hereditary) diseases (diseases which are effectively and selectively delivered to in-vivo targeted sites, such as macular degeneration, diabetic retinal degeneration, hereditary retinal degeneration, cancer, cerebral diseases, liver diseases and the like).

Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.

The application relates to specific binding members that bind OX40. The specific binding members comprise an OX40 antigen-binding site located in a constant domain of the specific binding member and find application in the treatment of cancer and infectious diseases, for example.

The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.

Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

The present invention relates to the field of adoptive immune cell therapy, in particular adoptive T cell therapy. The invention provides a switch receptor capable of efficiently converting the immunosuppressive signal of TGFβ that is typically present in the hostile tumor environment of solid tumors into a co-stimulatory signal that improves T cell activation and that is safe to use in therapy. Also provided are nucleic acids encoding the switch receptor, cell expressing said receptor and pharmaceutical compositions comprising said cells, in particular, for treatment of cancer or an infectious disease, e.g., by adoptive T cell therapy of a solid tumor.

Compositions and methods for treating a cancer or an infectious disease by delivering a compound comprising a polymeric backbone and a STING agonist covalently linked by a stimulus responsive linker are provided.

The invention discloses a method for extracting tumor and infectious disease body fluid free nucleic acid, a kit and application. The extraction method provided by the invention is high in extraction efficiency; through comparison, the extraction quality is 10 times that of a traditional kit. The kit comprises a specific MOF adsorption reagent, a lysis solution, a separating agent and a nucleic acid storage tube, the specific MOF adsorption reagent can capture free nucleic acid in body fluid of a patient through specific immunomagnetic beads, and then the free nucleic acid is separated and extracted through the lysis solution and the separating agent. According to the kit provided by the invention, free nucleic acid in tumor or infectious disease body fluid can be specifically extracted, interference of other normal cell DNA is eliminated, and the kit can be used for scientific research or clinical diagnosis analysis such as PCR amplification, gene expression, gene sequencing, chip detection, library construction and high-throughput sequencing, so that the subsequent detection result is more accurate, and the detection efficiency is improved. And the detection effect is better.

The invention relates to the technical field of image processing, and provides a CT image clear processing method, system and equipment for pulmonary infectious diseases, and the method comprises the steps: screening out the edge pixel points of all pulmonary blood vessels according to an authenticity evaluation coefficient, and obtaining the edge pixel points of the pulmonary blood vessels; according to the gray level distribution condition of the pixel points in each lung blood vessel edge area and the authenticity evaluation coefficient, obtaining a frosted shadow feature value of each lung blood vessel edge area; obtaining a lung attrition lesion area; according to a difference condition of gray values of pixel points between the lung attrition lesion area and the surrounding lung attrition lesion area, obtaining a window width adjustment amplitude of the lung image of the patient; and performing window width adjustment on the lung image of the patient according to the window width adjustment amplitude to obtain the adjusted lung image of the patient. According to the invention, more detailed and clearer position and form of the lung lesion area can be provided through the adjusted lung image of the patient.

The present invention relates to the field of medical equipment technology, and specifically to a mobile inspection vehicle. The present invention provides a mobile inspection vehicle equipped with a negative pressure isolation endoscope operation device, including a negative pressure chamber on the inspection vehicle, a through-hole structure is provided on the right side of the rear end of the negative pressure chamber, and an endoscope inspection component including an upper barrel, a second barrel and a lower barrel connected in sequence on the lower side of a first circle is provided on the through-hole structure, and an endoscope inspection channel is provided in the barrel, and the outer side of the first circle is sealed and fixedly connected to the inner circle of the through-hole structure, and a plurality of transversely arranged first negative pressure vents are provided in the middle of the upper barrel, and the endoscope inspection component and the auxiliary inspection component can effectively prevent medical staff from being infected. The present invention is usually used as a conventional negative pressure isolation transport vehicle. When endoscopic examination and treatment are required for patients with severe respiratory infectious diseases, it can prevent medical staff from being infected and avoid the spread of severe respiratory infectious diseases.

The invention provides a method and a kit for quantitative detection of recombinant redistribution of a Databa virus based on a multiple digital PCR (Polymerase Chain Reaction) technology, and belongs to the field of infectious disease monitoring. The method comprises the following steps: providing a to-be-detected sample containing segmented viruses and viral nucleic acid; detecting nucleic acid by using a plurality of multiple digital PCR reaction systems containing specific primer pairs and fluorescence labeled probes; amplifying according to a fluorescence coding rule, collecting and analyzing multi-channel fluorescence signals, and calculating the absolute copy number of each genotype; and based on copy number analysis genotype intra-fragment distribution proportion and inter-fragment combination mode, evaluating characteristics and frequency of virus recombination reconfiguration events. According to the detection method and the kit provided by the invention, accurate quantification of all main genotypes of the Databa virus can be realized.

To provide antibodies to TIGIT.SOLUTION: The invention provides monoclonal antibodies that specifically bind to TIGIT. The monoclonal antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications. The invention provides, inter alia, an antibody that competes with any of TIG1, TIG2 and TIG3 for binding to human TIGIT.SELECTED DRAWING: Figure 1

The present invention is a two-state feedback controller that takes into account the influence of spatio-temporal diffusion and individual contact heterogeneity. The controller design method includes: Step 1: Establish an SIR epidemic model; Step 2: Apply a two-state feedback controller to the SIR epidemic model; Step 3: Linearize the SIR epidemic model under the action of the two-state feedback controller at the equilibrium point to obtain the characteristic equation of the linearized controlled SIR epidemic model; Step 4: Select the time delay as the bifurcation parameter, and through stability analysis and bifurcation analysis of the characteristic equation of the linearized controlled SIR epidemic model, select appropriate state feedback parameters to make the model locally asymptotically stable near the equilibrium point. The two-state feedback controller of the present invention can perform feedback regulation control according to the state variables of susceptible individuals and infected individuals at the same time, and does not affect the characteristics of the original system, so as to efficiently and safely regulate the virus transmission process.

The present invention relates to antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and / or expand T effector cell populations or function. For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.

Devices, systems, and methods can be used for the automated production of dendritic cells (DC) from dendritic cell progenitors, such as monocytes obtained from peripheral blood, and the automated generation of immunotherapeutic products from those dendritic cells, all within a closed system. The invention makes it possible to obtain sufficient quantities of a subject's own DC for use in preparing and characterizing vaccines, for activating and characterizing the activation state of the subject's immune response, and to aid in preventing and / or treating cancer or infectious disease.

The present disclosure relates to methods, compositions and kits for concentrating and purifying at least one target analyte from a clinical biological sample. In some embodiments, the methods involve one or more aqueous two phase system (ATPS) compositions and at least one solid phase medium. Some embodiments provide a kit comprising one or more ATPS compositions, a binding buffer; and a solid phase medium. Other embodiments provide methods of treating cancer or infectious disease in a patient in need thereof.

This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.

A combined Chinese yam tuber growth groove arranged in a trench belongs to agricultural planting appliances, the Chinese yam tuber growth groove comprises a combination part, a space part and a base, the combination part is used for overlapping an upper Chinese yam tuber growth groove and a lower Chinese yam tuber growth groove, and the Chinese yam tuber growth grooves are combined to form a Chinese yam tuber growth space. According to the Chinese yam tuber growing device, Chinese yam tubers are separated from soil, occurrence of soil infectious diseases is avoided, growth resistance of the Chinese yam tubers is reduced, and the Chinese yam tuber growing device has the advantages that the Chinese yam tuber growing device is simple in structure, convenient to use and high in yield, and the yield of the Chinese yam tubers is increased. Chinese yam tubers grow in the shallow soil layer, the planting density is increased, the tower furrow phenomenon is avoided, the yield and quality of Chinese yams are improved, the plot planting limitation is overcome, the planting range is expanded, mechanical planting is achieved, and the income of farmers is increased.

The present disclosure relates to compositions comprising lipid nanoparticles (LNPs) configured for targeting dendritic cells. In particular, the present disclosure provides LNPs comprising a serine-based helper-lipid, a PEG lipid, an ionizable lipid, a cholesterol component, and one or more nucleic acids. The present disclosure provides use of the LNPs for the delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in various therapeutics, such as for the treatment of cancer or autoimmune diseases or prevention of infectious diseases. Finally, methods are provided for preparing such LNPs.

Provided is a dendritic cell activator that contains, as an active ingredient, a component derived from a natural product which has been eaten for many years and the safety of which has been empirically confirmed, and that is used for inducing or promoting an acquired immune response effective against cancer or infectious disease. Specifically provided are: a dendritic cell activator containing, as an active ingredient, 5-(3,5-dihydroxyphenyl)-y-valerolactone represented by formula (I); and a medicine, a supplement, and a food or beverage each containing the compound represented by formula (I) as an active ingredient. [The configuration of the wavy line may be either R-form or S-form.]

Provided herein are uses for an immunostimulatory compound for stimulating an immune response when administered either alone or as an adjuvant in a vaccine. Also provided herein are kits, compositions, and methods of administration for the compound described for proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease, in a subject in need thereof. Using the compound as a vaccine adjuvant enables effective immunization in vulnerable populations.

Disclosed are substituted indole compounds and compositions. The substituted indole compounds and compositions can be used for treating or preventing acute renal failure in a subject. The compounds and compositions can also be used for treating an infectious disease or cancer.

Disclosed herein are protective apparatuses, and associated systems, for minimizing the risk of transmission of SARS-CoV-2 and / or other infectious diseases between individuals in close proximity to one another including, for example, transmission through droplets projecting from the mouth or nasal region of an infected individual. Said apparatuses may comprise a substantially transparent shield component and a handle component comprising a connecting aspect. The protective apparatuses may comprise light emitting diodes and associated control means. The protective apparatuses of the present disclosure may further comprise a camera communicatively connected to a display screen.